Eesti - eesti - Ravimiamet

chanelle pharmaceuticals manufacturing limited - prednisoloon+mikonasool+polümüksiin b - kõrvatilgad, suspensioon - 5mg+23mg+5500rÜ 1ml 15ml 1tk; 5mg+23mg+5500rÜ 1ml 30ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

avimedical b.v. - itraconazole - antimycotics süsteemseks kasutamiseks, triasooli derivaadid, itraconazole - lind - ravi aspergillosis ja kandidoos kaaslane linnud,.

Euroopa Liit - eesti - EMA (European Medicines Agency)

actavis group ptc ehf - imatiniib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. mõju imatinib tulemuste kohta luuüdi siirdamine ei ole kindlaks. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. kogemus imatinib patsientidel mds/mpd seotud pdgfr geeni taas-kord on väga piiratud. puuduvad kontrollitud uuringud, mis näitab kliiniline kasu või suurenenud ellujäämise eest need haigused.

Eesti - eesti - Ravimiamet

radaydrug kft. - kolekaltsiferool - õhukese polümeerikattega tablett - 30000rÜ 1tk; 30000rÜ 3tk; 30000rÜ 2tk

Eesti - eesti - Ravimiamet

stada arzneimittel ag - mirtasapiin - õhukese polümeerikattega tablett - 30mg 1000tk; 30mg 100tk; 30mg 500tk; 30mg 20tk; 30mg 200tk; 30mg 150tk; 30mg 28tk; 30mg 90tk; 30mg 60tk; 30mg 350tk; 30mg 300tk; 30mg 40tk; 30mg 110tk; 30mg 250tk; 30mg 50tk; 30mg 98tk; 30mg 48tk

Eesti - eesti - Ravimiamet

stada arzneimittel ag - mirtasapiin - õhukese polümeerikattega tablett - 15mg 40tk; 15mg 20tk; 15mg 250tk; 15mg 50tk; 15mg 500tk; 15mg 200tk; 15mg 300tk; 15mg 14tk; 15mg 350tk; 15mg 150tk

Eesti - eesti - Ravimiamet

radaydrug kft. - kolekaltsiferool - õhukese polümeerikattega tablett - 7000rÜ 4tk; 7000rÜ 8tk; 7000rÜ 12tk

Eesti - eesti - Ravimiamet

opella healthcare france s.a.s. - drotaveriin - õhukese polümeerikattega tablett - 40mg 24tk

Eesti - eesti - Ravimiamet

radaydrug kft. - kolekaltsiferool - õhukese polümeerikattega tablett - 1000rÜ 30tk; 1000rÜ 90tk; 1000rÜ 60tk

Eesti - eesti - Ravimiamet

pharmaswiss ceska republika s.r.o. - pemetrekseed - infusioonilahuse kontsentraadi pulber - 500mg 1tk